$BLUE Form 8-K

0
657

Form 8-K for BLUEBIRD BIO, INC.


15-Dec-2016

Regulation FD Disclosure, Financial Statements and Exhibits

Item 7.01Regulation FD DisclosureOn December 15, 2016, bluebird bio, Inc. (“bluebird”) issued a press release that bluebird and Apceth Biopharma GmbH, have entered into a strategic manufacturing agreement providing for the anticipated future European commercial production of bluebird’s Lenti-D product candidate for cerebral adrenoleukodystrophy and bluebird’s LentiGlobin product candidate for transfusion-dependent ?-thalassemia. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01Financial Statements and Exhibits.(d) Exhibits

Exhibit No. Description
99.1 Press release issued by bluebird bio, Inc. on December 15, 2016.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here